FOXO3 and metabolic dysfunction-associated steatotic liver disease: In numerous potential targets, FOXO3 was selected for further analysis as it has been reported to be closely associated with lipid metabolism and insulin resistance in HFD-induced NAFLD (Zhu et al., 2017).